Short answer
Personalis, Inc. (PSNL) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $14M (down 43.6% year over year) with net income of −$22M.
Q3 2025 key financials · XBRL
- Revenue
- $14M
- −43.6% YoY · −15.7% QoQ
- Net income
- −$22M
- +44.6% YoY · −8.0% QoQ
- Operating margin
- -160.7%
- EPS (diluted)
- −$0.24
- +65.2% YoY · −4.3% QoQ
Source: XBRL data from the Personalis, Inc. (PSNL) Q3 2025 10-Q on SEC EDGAR. USD.
Personalis, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $14.495M, down $11.214M or 44% YoY
- Gross margin 13.2% vs 34.0% YoY; operating margin -160.7% vs -56.0%
- Clinical diagnostics best performer, revenue $384K, up 42%; enterprise sales worst, $650K, down 88%
- Cash and investments $150.515M vs $185.009M at December 31, 2024
- VA MVP task order up to $13.5M; Natera relationship not expected beyond 2025
Risk Factors
- Newly triggered VA MVP risk: fourth 2025 task order worth up to $13.5 million, with no guarantee of renewal
- Customer concentration: Moderna represented 25% of nine-month 2025 revenue, while top five customers contributed 65%
- Natera transition risk: company does not expect a long-term relationship beyond 2025 as Natera plans to bring services in-house
- Profitability risk: nine-month 2025 net loss $57.5 million and accumulated deficit $607.4 million
- Competitive regulatory risk: non-FDA-cleared companion diagnostics may be limited to off-label use in FDA-labeled oncology markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Personalis, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.